14
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      DIMENSÕES QUE INTERFEREM NA ADESÃO À MEDICAÇÃO NOS TRANSTORNOS RELACIONADOS ÀS SUBSTÂNCIAS: REVISÃO INTEGRATIVA Translated title: DIMENSIONS THAT INTERFERE WITH ADHERENCE TO MEDICATION IN SUBSTANCE-RELATED DISORDERS: INTEGRATIVE REVIEW Translated title: DIMENSIONEES QUE INLFUYEN EN LA ADHESIÓN A LA MEDICACIÓN EN LOS TRASTORNOS ASOCIADOS A SUSTANCIAS: REVISIÓN INTEGRATIVA

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          RESUMO Objetivo Analisar a produção científica acerca das dimensões que interferem na adesão à terapêutica medicamentosa de pessoas com transtornos mentais relacionados ao uso de substância, no período de 2006 a abril de 2017. Método Revisão Integrativa da Literatura a partir de três bancos de dados, LILACS, CINAHL e PUBMED, realizada em abril de 2017. Resultados Foram analisados 43 estudos que atendiam aos critérios de elegibilidade. A análise dos estudos possibilitou identificar fatores que impactam positiva ou negativamente a adesão à terapêutica medicamentosa, agrupados de acordo com as cinco dimensões determinantes para a adesão proposta pela Organização Mundial da Saúde, sendo elas: socioeconômica, equipe/sistema de saúde, doença, tratamento, e indivíduo/paciente. Conclusão Embora a terapêutica medicamentosa seja imprescindível no gerenciamento da pessoa com transtorno relacionado a substâncias, muitas vezes representa um desafio devido às diferentes dimensões interativas que influenciam diretamente no processo de adesão.

          Translated abstract

          ABSTRACT Objective To analyze the scientific production about the dimensions that interfere in the adherence to pharmacological therapy of individuals with mental disorders related to substance abuse from 2006 to April 2017. Method Integrative literature review of publications indexed in the following three databases LILACS, CINAHL and PUBMED, performed in April 2017. Results The 43 studies that met the eligibility criteria were analyzed. Such analysis made it possible to identify factors that have positive or negative impact on adherence to pharmacological therapy, grouped according to the five dimensions that determine the adherence proposed by the World Health Organization, namely: socioeconomic, health team/system, disease, treatment, and individual/patient. Conclusion Although pharmacological therapy is crucial in the management of individuals with substance-related disorders, implementing the treatment is challenging because of the different interactive dimensions that directly impact the process of treatment adherence.

          Translated abstract

          RESUMEN Objetivo Analizar la producción científica acerca de las dimensiones que influyen en la adhesión a la terapéutica medicamentosa de personas con trastornos mentales asociados al uso de sustancia, en el periodo de 2006 a abril de 2017. Método Revisión Integrativa de la Literatura a partir de tres bancos de datos, LILACS, CINAHL y PUBMED, hecha en abril de 2017. Resultados Se evaluaron 43 estudios que atendían a los criterios de elegibilidad. El análisis de los estudios posibilitó identificar factores que tienen impacto positivo o negativo en la adhesión a la terapéutica medicamentosa. Esos factores se organizaron de acuerdo con las cinco dimensiones determinantes para la adhesión que propuso la Organización Mundial de la Salud: socioeconómica, equipo/sistema de salud, enfermedad, tratamiento, e individuo/paciente. Conclusión A pesar de que la terapéutica medicamentosa es imprescindible en la administración de la persona con trastorno asociado a substancias, muchas veces representa un desafío a causa de las distintas dimensiones interactivas que influencian directamente en el proceso de adhesión.

          Related collections

          Most cited references51

          • Record: found
          • Abstract: found
          • Article: not found

          Predictors of methadone treatment retention from a multi-site study: a survival analysis.

          Longer tenure in methadone treatment has been associated with positive outcomes such as reductions in drug use and crime, HIV seroconversion, and overdose death. Retention in treatment was examined for 351 opioid-dependent individuals who had been newly admitted to one of six methadone programs in Baltimore, Maryland. Cox proportional hazards regression was used to predict number of days retained in treatment to 90 days from baseline ASI Composite scores and Treatment Motivation scales. A second analysis predicted days in treatment to 365 days using the same baseline variables plus 3-month Motivation scales, Patient Satisfaction scales, and methadone dose in the 248 individuals who had remained in treatment at least 3 months. Analyses held constant gender, race, age, whether participants had a history of regularly smoking cocaine, whether participants were on parole/probation, and program site. Retention at 90 days was predicted by female gender, and greater baseline Treatment Readiness (p=.005) but lower Desire for Help (p=.010). Retention at 365 days was predicted by higher baseline ASI Medical Composite scores (p=.037) and lower Legal Composite scores (p=.039), higher 3-month Treatment Satisfaction scores (p=.008), and higher dose (p=.046). Greater satisfaction with treatment at 3 months was a significant predictor of retention at 12 months, indicating the importance of understanding the role satisfaction plays in determining retention. Greater severity of legal problems was associated with shorter retention, suggesting that program efforts to increase services to criminal justice patients (e.g., legal counseling) may constitute a useful addition to treatment. Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Treating Homeless Opioid Dependent Patients with Buprenorphine in an Office-Based Setting

            Context Although office-based opioid treatment with buprenorphine (OBOT-B) has been successfully implemented in primary care settings in the US, its use has not been reported in homeless patients. Objective To characterize the feasibility of OBOT-B in homeless relative to housed patients. Design A retrospective record review examining treatment failure, drug use, utilization of substance abuse treatment services, and intensity of clinical support by a nurse care manager (NCM) among homeless and housed patients in an OBOT-B program between August 2003 and October 2004. Treatment failure was defined as elopement before completing medication induction, discharge after medication induction due to ongoing drug use with concurrent nonadherence with intensified treatment, or discharge due to disruptive behavior. Results Of 44 homeless and 41 housed patients enrolled over 12 months, homeless patients were more likely to be older, nonwhite, unemployed, infected with HIV and hepatitis C, and report a psychiatric illness. Homeless patients had fewer social supports and more chronic substance abuse histories with a 3- to 6-fold greater number of years of drug use, number of detoxification attempts and percentage with a history of methadone maintenance treatment. The proportion of subjects with treatment failure for the homeless (21%) and housed (22%) did not differ (P = .94). At 12 months, both groups had similar proportions with illicit opioid use [Odds ratio (OR), 0.9 (95% CI, 0.5–1.7) P = .8], utilization of counseling (homeless, 46%; housed, 49%; P = .95), and participation in mutual-help groups (homeless, 25%; housed, 29%; P = .96). At 12 months, 36% of the homeless group was no longer homeless. During the first month of treatment, homeless patients required more clinical support from the NCM than housed patients. Conclusions Despite homeless opioid dependent patients’ social instability, greater comorbidities, and more chronic drug use, office-based opioid treatment with buprenorphine was effectively implemented in this population comparable to outcomes in housed patients with respect to treatment failure, illicit opioid use, and utilization of substance abuse treatment.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Factors predicting retention in treatment: 10-year experience of a methadone maintenance treatment (MMT) clinic in Israel.

              The aims were to identify predictors of treatment retention in an Israeli methadone maintenance treatment (MMT) clinic, and to compare the findings to other international settings. We prospectively studied 492 patients admitted since 1993 through 10 years to an Israeli MMT clinic associated with a university-affiliated tertiary care medical center. Analyses (Kaplan Meier and Cox regression) included methadone dose and urinalysis results (for methadone, cocaine, opiates, benzodiazepines, THC, amphetamines) of each patient in the first month and after 1 year in treatment (or during the last month if the stay was >3 months and <1 year) and patients' characteristics (modified ASI). The 1-year retention rate was 74.4%; 65.8% stopped opiate abuse after 1 year in treatment. On admission, 13.6% of patients had used cocaine: there was a net decrease of 61.6% after 1 year. Factors predicting prolonged retention in MMT treatment (Cox regression) were daily methadone dose of 100mg or greater, negative urine for opiates after 1 year, and being a parent on admission. We conclude that our good outcome results (high rate of retention after 1 year (74.4%), high proportion of opiate abuse cessation (65.8%), and net reduction in cocaine abuse, similar to normal standards in other MMT clinics elsewhere in the world, justify the expansion of the MMT clinic network in Israel in order to make treatment available to all those who need it. A protocol favoring higher methadone dosage as appropriate is recommended.
                Bookmark

                Author and article information

                Contributors
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Journal
                ce
                Cogitare Enfermagem
                Cogitare enferm.
                Universidade Federal do Paraná (Curitiba, PR, Brazil )
                1414-8536
                2176-9133
                2019
                : 24
                : e58170
                Affiliations
                [3] Curitiba Paraná orgnameUniversidade Federal do Paraná Brazil
                [5] Cascavel PR orgnameHospital Universitário do Oeste do Paraná Brasil
                [4] Curitiba PR orgnameCentro de Atenção Psicossocial Álcool e Drogas de Curitiba Brasil
                [2] Curitiba Paraná orgnameUniversidade Federal do Paraná Brazil
                [1] Curitiba PR orgnameCentro de Atenção Psicossocial Infantil de São José dos Pinhais Brasil
                Article
                S1414-85362019000100506
                10.5380/ce.v24i0.58170
                f1e98600-4c64-4535-875c-aa16a2584a8b

                This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

                History
                : 15 April 2018
                : 16 January 2019
                Page count
                Figures: 0, Tables: 0, Equations: 0, References: 58, Pages: 0
                Product

                SciELO Revista de Enfermagem

                Categories
                Revisão

                Trastornos asociados al Uso de Sustancias,Adesão a medicação,Cooperação do paciente,Tratamento farmacológico,Transtornos Relacionados ao Uso de Substâncias,Saúde mental,Adherence to medication,Patient cooperation,Pharmacological treatment,Substance-Related Disorders,Mental health,Adhesión a medicación,Cooperación del paciente,Tratamiento farmacológico,Salud mental

                Comments

                Comment on this article